The Lancet - Respiratory Medicine: Triple inhaled aerosol therapy has clinical significance improvement in uncontrolled asthma patients.

The positive complete results of the Phase III KALOS and LOGOS trials published in The Lancet Respiratory Medicine show that in uncontrolled asthma patients, AstraZeneca's Bevespi Aerosphere demonstrated a significantly and clinically meaningful improvement compared to the inhaled corticosteroid/long-acting beta2-agonist combination inhaler Symbicort, PT009, and the combination of Symbicort and PT009. Bevespi is a triple combination inhalation aerosol that delivers inhaled corticosteroid/long-acting beta2-agonists and long-acting muscarinic antagonist through a single inhaler with a fixed dose.